Glycyrrhetinic acid

Glycyrrhetinic acid
Product Name Glycyrrhetinic acid
CAS No.: 471-53-4
Catalog No.: CFN99152
Molecular Formula: C30H46O4
Molecular Weight: 470.64 g/mol
Purity: >=98%
Type of Compound: Triterpenoids
Physical Desc.: Powder
Targets: PERK | CDK | E2F‑1 | AChR
Source: The roots of Glycyrrhize glabra L.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $30/20mg
Glycyrrhetinic acid, an AChE activator, has anti-inflammatory,and antileukaemic activities. It is a potent inducer of mitochondrial permeability transition and can trigger the pro-apoptotic pathway, it has a low but definite affinity for mineralocorticoid receptors and thus appears to have a direct mineralocorticoid action.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Molecules2022, 27(14):4601
  • Dent Mater J.2020, 39(4):690-695
  • Oxid Med Cell Longev.2022, 2022:9139338.
  • Nutraceutical Research . 2021, 19(1),p90-105.
  • Microchemical Journal2023, 194:109249
  • Asian J Beauty Cosmetol2019, 17(3):287-294
  • Food Sci Nutr.2023, 00:1-10.
  • Sci Rep.2017, 7(1):3249
  • Drug Des Devel Ther.2020, 14:61-71
  • Biomed Pharmacother.2024, 173:116319.
  • Wilforlide A acetate

    Catalog No: CFN97336
    CAS No: 84104-80-3
    Price: $390/5mg
    Polpunonic acid

    Catalog No: CFN96834
    CAS No: 33600-93-0
    Price: Inquiry(manager@chemfaces.com)
    Salaspermic acid

    Catalog No: CFN96837
    CAS No: 71247-78-4
    Price: Inquiry(manager@chemfaces.com)
    Canophyllal

    Catalog No: CFN89150
    CAS No: 14440-40-5
    Price: Inquiry(manager@chemfaces.com)
    Bryonolic acid

    Catalog No: CFN98260
    CAS No: 24480-45-3
    Price: $338/5mg
    Glycyrrhetinic acid

    Catalog No: CFN99152
    CAS No: 471-53-4
    Price: $30/20mg
    28-Hydroxy-3-oxoolean-12-en-29-oic acid

    Catalog No: CFN97747
    CAS No: 381691-22-1
    Price: Inquiry(manager@chemfaces.com)
    22-Hydroxy-3-oxoolean-12-en-29-oic acid

    Catalog No: CFN99487
    CAS No: 144629-84-5
    Price: Inquiry(manager@chemfaces.com)
    3,22-Dihydroxyolean-12-en-29-oic acid

    Catalog No: CFN97288
    CAS No: 808769-54-2
    Price: Inquiry(manager@chemfaces.com)
    Triptocallic acid D

    Catalog No: CFN98018
    CAS No: 201534-09-0
    Price: Inquiry(manager@chemfaces.com)
    Int J Oncol. 2015 Mar;46(3):981-8.
    Glycyrrhetinic acid induces G1‑phase cell cycle arrest in human non‑small cell lung cancer cells through endoplasmic reticulum stress pathway.[Pubmed: 25573651]
    Glycyrrhetinic acid (GA) is a natural compound extracted from liquorice, which is often used in traditional Chinese medicine.
    METHODS AND RESULTS:
    The purpose of the present study was to investigate the antitumor effect of GA in human non‑small cell lung cancer (NSCLC), and its underlying mechanisms in vitro. We have shown that GA suppressed the proliferation of A549 and NCI‑H460 cells. Flow cytometric analysis showed that GA arrested cell cycle in G0/G1 phase without inducing apoptosis. Western blot analysis indicated that GA mediated G1‑phase cell cycle arrest by upregulation of cyclin‑dependent kinase inhibitors (CKIs) (p18, p16, p27 and p21) and inhibition of cyclins (cyclin‑D1, ‑D3 and ‑E) and cyclin‑dependent kinases (CDKs) (CDK4, 6 and 2). GA also maintained pRb phosphorylation status, and inhibited E2F transcription factor 1 (E2F‑1) in both cell lines. GA upregulated the unfolded proteins, Bip, PERK and ERP72. Accumulation of unfolded proteins in the endoplasmic reticulum (ER) triggered the unfolded protein response (UPR), which could be the mechanism by which GA inhibited cell proliferation in NSCLC cells. GA then coordinated the induction of ER chaperones, which decreased protein synthesis and induced cell cycle arrest in the G1 phase.
    CONCLUSIONS:
    This study provides experimental evidence to support the development of GA as a chemotherapeutic agent for NSCLC.
    Biochem Pharmacol. 2003 Dec 15;66(12):2375-9.
    Glycyrrhetinic acid-induced permeability transition in rat liver mitochondria.[Pubmed: 14637195]
    Glycyrrhetinic acid, a hydrolysis product of one of the main constituents of licorice, the triterpene glycoside of glycyrrhizic acid, when added to rat liver mitochondria at micromolar concentrations induces swelling, loss of membrane potential, pyridine nucleotide oxidation, and release of cytochrome c and apoptosis inducing factor. These changes are Ca(2+) dependent and are prevented by cyclosporin A, bongkrekic acid, and N-ethylmaleimide. All these observations indicate that Glycyrrhetinic acid is a potent inducer of mitochondrial permeability transition and can trigger the pro-apoptotic pathway.
    J. Pharm. Pharmacol., 2011, 10(1):613-20.
    The antiinflammatory activity of glycyrrhetinic acid and derivatives.[Reference: WebLink]
    The anti-inflammatory activities of different fractions of Glycyrrhetinic acid or glycyrrhetic acid and some of its derivatives have been assessed in laboratory animals. Some, but not all, preparations have been found to be active using four established methods for testing anti-inflammatory drugs. The findings provide a scientific basis for the clinical use of these compounds in inflammatory diseases, and may explain the discrepancies in the early clinical trials with this drug.
    Evid Based Complement Alternat Med . 2017;2017:3470320.
    Protective Effect of 18 β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats[Pubmed: 28572827]
    Abstract Triptolide (TP) is the major active component of Tripterygium wilfordii Hook F (TWHF) and possesses multiple pharmacological effects. However, hepatotoxicity of TP which is one of the toxic properties slows its progression in clinical application. 18β-Glycyrrhetinic acid (GA) is the main bioactive ingredient of Licorice (Glycyrrhiza glabra L.), a herbal medicine famous for its detoxification. This study aims to investigate whether GA possesses protective effect against TP-induced hepatotoxicity in rats. TP interference markedly elevated serum levels of ALT, AST, and ALP, caused evident liver histopathological changes, and elevated hepatic TNF-α, IL-6, IL-1β, and IFN-γ as well as nuclear translocation of NF-κB. TP also significantly elevated liver MDA and declined hepatic activities of SOD, CAT, and GSH-Px. Assay of TUNEL and apoptosis proteins (Bax, Bcl-2, and active caspase-3) showed that TP induced severe hepatocellular apoptosis. In contrast, low-dose GA (50 mg/kg) significantly reversed TP-induced changes above. However, high-dose GA (100 mg/kg) had no such effect. Overall, these findings indicated that low-dose GA but not high-dose GA exhibited a protective effect against TP-induced hepatotoxicity in rats by anti-inflammation, antioxidation, and antiapoptosis, which suggests that the doses of GA/Licorice should be carefully considered when used together with TWHF or TWHF preparations.
    Bioorg Med Chem. 2014 Jul 1;22(13):3370-8.
    Amino derivatives of glycyrrhetinic acid as potential inhibitors of cholinesterases.[Pubmed: 24853320]
    The development of remedies against the Alzheimer's disease (AD) is one of the biggest challenges in medicinal chemistry nowadays. Although not completely understood, there are several strategies fighting this disease or at least bringing some relief. During the progress of AD, the level of acetylcholine (ACh) decreases; hence, a therapy using inhibitors should be of some benefit to the patients. Drugs presently used for the treatment of AD inhibit the two ACh controlling enzymes, acetylcholinesterase as well as butyrylcholinesterase; hence, the design of selective inhibitors is called for.
    METHODS AND RESULTS:
    Glycyrrhetinic acid seems to be an interesting starting point for the development of selective inhibitors. Although its glycon, Glycyrrhetinic acid is known for being an AChE activator, several derivatives, altered in position C-3 and C-30, exhibited remarkable inhibition constants in micro-molar range. Furthermore, five representative compounds were subjected to three more enzyme assays (on carbonic anhydrase II, papain and the lipase from Candida antarctica) to gain information about the selectivity of the compounds in comparison to other enzymes. In addition, photometric sulforhodamine B assays using murine embryonic fibroblasts (NiH 3T3) were performed to study the cytotoxicity of these compounds. Two derivatives, bearing either a 1,3-diaminopropyl or a 1H-benzotriazolyl residue, showed a BChE selective inhibition in the single-digit micro-molar range without being cytotoxic up to 30μM.
    CONCLUSIONS:
    In silico molecular docking studies on the active sites of AChE and BChE were performed to gain a molecular insight into the mode of action of these compounds and to explain the pronounced selectivity for BChE.
    Int J Mol Cell Med. 2014 Fall;3(4):272-8.
    Glycyrrhetinic Acid Induces Apoptosis in Leukemic HL60 Cells Through Upregulating of CD95/ CD178.[Pubmed: 25635254]
    Acute leukemia is characterized by the accumulation of neoplastic cells in the bone marrow and peripheral blood. Currently, chemotherapy and differentiating agents have been used for the treatment of leukemia. Recently, plant extracts, either alone or in combination with chemo agents, have been proposed to be used for the treatment of cancers.
    METHODS AND RESULTS:
    The aim of the present research was to study the cytotoxicity and apoptosis effects of an active licorice-derived compound, Glycyrrhetinic acid (GA), on human leukemic HL60 cells. HL60 cells were cultured in RPMI1640 containing 10% fetal bovine serum. Cells were treated with different doses of GA and their viability and proliferation were detected by dye exclusion and 3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assays. Apoptosis induction and expression of CD95 and CD178 were analyzed by flow cytometry. We observed that GA decreases cell viability and suppresses cells proliferation in a dose- dependent manner. In addition, our flow cytometry data show that GA not only induces apoptosis in HL60 cells, but also upregulates both CD95 and CD178 expression on the cell surface of these cells in a dose-dependent manner.
    CONCLUSIONS:
    The combination of GA with cytotoxic drugs and differentiation agents requires further investigation.
    Carasinol D

    Catalog No: CFN95044
    CAS No: 1072797-66-0
    Price: $333/5mg
    3''-O-Galloylmyricitrin

    Catalog No: CFN95057
    CAS No: 143202-36-2
    Price: $333/5mg
    Orientalide

    Catalog No: CFN95136
    CAS No: 72704-05-3
    Price: $368/5mg
    Silybin A

    Catalog No: CFN95149
    CAS No: 22888-70-6
    Price: $318/20mg
    24-Hydroxymomordicine III

    Catalog No: CFN95169
    CAS No: N/A
    Price: $318/5mg
    Schisphenin E

    Catalog No: CFN95223
    CAS No: 1311376-52-9
    Price: $318/5mg
    Physalin X

    Catalog No: CFN95329
    CAS No: 72497-31-5
    Price: $318/5mg
    4'-O-Methyllucenin II (Diosmetin 6,8-di-C-glucoside)

    Catalog No: CFN95344
    CAS No: 98813-28-6
    Price: $318/10mg
    Foliachinenoside C

    Catalog No: CFN95361
    CAS No: 1041180-87-3
    Price: $368/5mg
    3-O-Methylellagic acid 3'-O-alpha-rhamnopyranoside

    Catalog No: CFN95375
    CAS No: 352280-34-3
    Price: $413/5mg